Member Info for P3T3R

"This company has huge potential but none of the future potential is reflected in the share price"
.
.
Could be slightly debatable, as best information still suggests a forward p/e of over 100 ...

From past experience, if everything goes to plan, I expect this one to declare a dividend in 2023. 10x cover will do nicely. Fingers crossed. :-)

"We made a 3 Mill profit last year on revenue of less than 9 Mill."
.
.
This "profit" was primarily a result of one of Financing Income (Note 10) which is a direct result of the Thermo Fisher Loan Waiver (£9.389m). Forecasts for FY just ended are for a LOSS of -0.1p EPS, although obviously I would be happy to see break even.

It is next year (ie Mar 21), and the years after that we should start to see accelerating results, which are currently forecast as 0.17p and 0.37p (Sharecast). These forecasts are very out of date. and do nottake account of recent events/RNSs.

Good post Florida ...

And don't forget that Lyn Rees has 14m reasons to be incentivised. Hopefully his sights are set on real money and not a bit of pocket change.

Where can peeps find those forecasts Smithy? They differ from the Sharecast numbers ...

I apologise to everyone who is might be still "underwater".

For new investors, and even if you have been at it a while, it is not pleasant watching your savings getting smaller and smaller ... Been there ... Done that ... Got the T-Shirt.

But I am fairly sure, for any timescale greater than a year, this is going to come good.

The link posted by baccky below is only one reason. The last official figures we have is 82000 tests, from a market size of 4m ie just over 2%. And that was just on TF platforms. Noe that we are on Illumina platforms, 2% of worldwide market would have us well in £££. The actual figure might not be known, but surely it is north of 18p.

https://www.globenewswire.com/news-release/2020/06/16/2048801/0/en/Non-Invasive-Prenatal-Testing-NIPT-Market-Worth-13-14-Billion-by-2027-Growing-at-a-CAGR-of-17-1-from-2019-Global-Opportunity-Analysis-and-Industry-Forecasts-by-Meticulous-Research.html

"Wish i did not ,f i had damp it in Twllow oil at 7 ,now had be laughing ..."

ROFLMAO - Hindsight investment at it's most basic.

Actually Twllow oil is a pretty bad choice. Many many others out there that are much better hindsight investments.

Thanks cringsing. Clearly states antigen testing. I should have dug deeper before posting earlier.

UNFORTUNATELY ... Is this an own goal ???
1. Clarigene ... test for whether someone is infected and is I believe and antigen test. "Clarigene(TM) SARS-CoV-2 test - a molecular PCR based COVID-19 assay, which is able to detect whether individuals are currently infected"
2. The Prova Immunity passport depends on testing for Antibodies ... which is not the clarigene test.

https://uk.advfn.com/stock-market/london/yourgene-health-YGEN/share-news/Yourgene-Health-PLC-COVID-19-testing-service-launc/82529198

https://provapro.com/

The average healthcare takeover premium 2017/2018 is 37.8% to the 4 week stock price. An eyeball of the monthly chart suggests roughly 18.5p * 1.378 = 25.5p.

I'm pretty sure vast majority of people are not here 25.5p. Given that LR has 14m options, I would be really really disappointed if LR decided to settle for a quick turn instead of turning us into a proper company.

He has the opportunity to build real wealth, both for himself and the shareholders.

Personally, I like that he doesn't "pump" every RNS. That is a big red flag in my book. State the facts and get on with business.

Would be interesting to see who is still here at 26p.

https://www.statista.com/statistics/978494/average-premiums-in-the-united-states-by-industry/

SIPP ???

Bakky, JAdam ... Good posts ... totally agree .

Field of Dreams .... LOL

Don't forget that even the "nominal" commission is offset against their share price gains ??? (RNS 18/02/2019) ...

They exercised 41,356,165 at an average exercise price is 9.2p per share

"Once Yourgene is cashflow positive it will pay modest commissions to Life Technologies on sales made in the Territories until a cap threshold of GBP6.5 million is reached (as described above) through either commission paid or realised share price gains"

"Considering the amounts of money these tests can generate it just makes no sense."

Bulk supply of test kits does seem to be very low margin priced from £8 per test in comparison to private testing where you will be charged typically £125-£150 each.

from £8.00 per test
100 Test kit £950.00
250 Test Kit £2000.00
https://www.clentlifescience.co.uk/co-diagnostic-coronavirus-2019-covid-19-ce-ivd-kit/

Maybe the fact Ygen have stated they are targeting the private sector means there is no conflict of interest between the companies? because right up till this week all the tweets and retweets of articles from YGEN have suggested all is well between NCYT and YGEN.

The RNS wording implies we are targeting high throughput laboratories as well, albeit not immediately ... "Will initially be a manual assay and development has commenced with a fully automated version aimed at high throughput laboratories to follow in the coming months"

Yes it did ... Smiley Face ... Managed to top up with 500k @sub10p ... Happy days.

NCYT test is an antigen test which tests whether you are in infected. The bad test re: refunds is an antibody tests which tests whether you have the antibodies.

https://www.telegraph.co.uk/news/2020/04/06/government-seeks-refund-millions-coronavirus-antibody-tests/

Ooooh, where's the popcorn ... BSD face off ... LOL